The world is on the cusp of a digital health transformation, and integrated healthcare data is already enhancing the way people access care, tackle disease and respond to treatments.
New technology is allowing healthcare professionals to begin personalising medicines, as well as informing much more sophisticated research. As a result, we are beginning to better understand how and why people respond differently to the same treatment or drug.
But there is the potential to do so much more.
Karen Lamb is a senior team member at GenV (Generation Victoria), a project led by the Murdoch Children’s Research Institute (MCRI) in the Australian city of Melbourne.
GenV plans to approach all babies born in the state of Victoria in 2020, and follow them for two years, asking their parents’ consent to take part throughout the baby’s childhood. It will put the state’s medical research at the forefront of this data revolution.
Lamb is a biostatistician, brought in to make sure the data from this world-first project is as accessible and useful for researchers as possible.
She says that the project is unique in the way it focusses on an entire population of newborns within a state or territory, rather than just a sample – which makes it one of the most ambitious children’s projects ever attempted.
The team is looking to amalgamate data that is already collected and stored separately during routine check-ups, to inform future research. For interested families, they additional genetic information from the children and their parents.
“Each person’s information is unique, but combine data from a large population and you can unravel valuable trends and patterns,” Lamb explains.
“By improving, combining and unifying the data, researchers will be able to do things like identify markers for disease; trends in obesity and cardiovascular disease; devise ways to diagnose and treat allergies; and provide a foundation for better integrated health data across Victoria.”
Melissa Wake, director of GenV, says that by 2035 the project’s mission is to have solved complex health, development and wellbeing issues for children now, and the adults they will become.
Wake says to create a study of this scale, the team looked at examples from overseas, such as the UK Biobank, the Norwegian Mother and Child Cohort Study, and the Japan Environment and Children’s Study.
“In the UK, their Biobank work has uncovered genes associated with Alzheimer’s disease and helped researchers to map genetic variants that increase the risk of depression,” Wake says.
Lamb says that expertise in biostatistics has been shown to be critical in assisting in the design of studies and in developing methodologies to tackle complex health questions.
“I can ensure that the data is protected, de-identified, and stored in a way that is easily accessible and relevant for researchers,” she says.
“This means scientists will be spending less time collecting, cleaning and refining data sets, and more time working on treatments for some of the world’s most challenging diseases. In addition, families will know that their data are not only safe and private, but helping other children in the future.”
Karen Lamb is among 30 Superstars of STEM featured in this weekly series prepared by Science & Technology Australia (STA) – to learn more about the program, visit the STA website.
Originally published by Cosmos as Finding the trends in newborn lives
Dion Pretorius is Communications and Policy Manager at Science & Technology Australia.
Read science facts, not fiction...
There’s never been a more important time to explain the facts, cherish evidence-based knowledge and to showcase the latest scientific, technological and engineering breakthroughs. Cosmos is published by The Royal Institution of Australia, a charity dedicated to connecting people with the world of science. Financial contributions, however big or small, help us provide access to trusted science information at a time when the world needs it most. Please support us by making a donation or purchasing a subscription today.